|
WO2020247872A1
|
|
T-cell depleting therapies
|
|
WO2020247670A1
|
|
Methods and compositions for treating autoimmune diseases
|
|
WO2020219964A1
|
|
Conditioning methods for gene therapy
|
|
WO2020219959A1
|
|
Anti-cd45 antibody drug conjugates and uses thereof
|
|
US2020376135A1
|
|
Fc silenced antibody drug conjugates (adcs) and uses thereof
|
|
WO2020219778A2
|
|
Anti-cd117 antibody-drug conjugates and uses thereof
|
|
WO2020219775A1
|
|
Anti-cd117 antibody-drug conjugates and uses thereof
|
|
WO2020219774A1
|
|
Anthracycline antibody-drug conjugates and uses thereof
|
|
WO2020219748A2
|
|
Anti-cd117 antibodies and uses thereof
|
|
WO2020219770A1
|
|
Anti-cd117 antibodies and uses thereof
|
|
WO2020146432A1
|
|
Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy
|
|
WO2020092694A2
|
|
Methods for hematopoietic stem and progenitor cell transplant therapy
|
|
WO2020092654A1
|
|
Anti-cd45 antibodies and conjugates thereof
|
|
WO2020092655A1
|
|
Methods for allogeneic hematopoietic stem cell transplantation
|
|
WO2020086776A1
|
|
Fc silenced antibody drug conjugates (adcs) and uses thereof
|
|
WO2020081840A1
|
|
Methods of treating cancer with aryl hydrocarbon receptor antagonists
|
|
WO2020051207A2
|
|
Aryl hydrocarbon receptor antagonists and methods of use
|
|
WO2020023556A1
|
|
Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
|
|
WO2020023559A1
|
|
Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy
|
|
CA3107383A1
|
|
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
